Human Thy-I antigen has a unique pattern of expression on haemopoietic cells: it has been found on a minority of thymocytes and late pre-B/early B cells (Ritter et al., 1983) . In immunodiagnosis of haemoblastoses this antigen is helpful as an additional marker for differentiation of malignant lymphoblasts (Tupitsyn et al., 1987; Peterson et al., 1986) . Thy-I antigen expression on cerebral tissue is one of its characteristic features as shown previously (Casper et al., 1977; Danon et al., 1980; McKenzie & Farbe, 1981) . With the use of anti-Thy-I monoclonal antibody (Mab) 390, Seeger et al. (1982) also found this antigen on fibroblasts and the majority of neuroblastomas. Recent investigations have demonstrated a more variable pattern of tissue distribution of normal and malignant cells expressing Thy-I antigen coded by the gene located in chromosome 1. This antigen has also been found on a number of small round cell tumours. Thus, Kl and MC 139 Mabs reacted with neurogen cells, fibroblasts, with most sarcomas, choriocarcinomas, teratocarcinomas and endothelial and unstriated muscle cells, while no reaction with normal and malignant epithelial cells was noted (Retting et al., 1985) . ICO-10 Mabs against Thy-I antigen also reacted with neuroblastoma cells in most cases and with some T-and B-cell leukaemias and lymphosarcomas (Zikiryakhodzhaev et al., 1987; Baryshnikov et al., 1985a) . K20 (CD 29) Mab recognising VLA molecular complexes are also helpful for immunophenotyping of tumours and haemoblastoses. Their pattern of tissue distribution is quite different (Amiot et al., 1986) . ICO-10 and K20 Mabs were shown to have different patterns of reactivity with some tumour cells, subpopulations of B-and T-cells (Baryshnikov, 1984; Amiot et al., 1986) . The choice of these two monoclonals was based on the results of pre-screening studies involving various solid tumours and 17 antibodies from the well established clasters of differentiation (CD 1, 2, 5, 7, 8, 10, 11, 15 (Baryshnikov, 1984; Baryshnikov et al., 1985b) .
Immunohistology
The expression of immunological markers was assayed in cryostat tumour serial sections in an indirect immunofluorescence (IF) procedure (all the cases listed above). In some cases (see Table I ) with a positive reaction the additional immunoenzyme staining was used. As second antibodies for the indirect IF test, F(ab)'2-fragments were used, prepared by the method of Janossy (1981) from FITC-labelled polyvalent rabbit antisera against mouse immunoglobulins (Gamaleya Institute of Epidemiology and Microbiology AMS USSR), diluted 1:20. In immunoenzyme assays the same dilution of peroxidase labelled antibodies against mouse globulins was used (Gamaleya Institute, Moscow). As control, supernatants of non-producing mouse myeloma R3-X63-Ag8.653 were used. The IF procedure in cryostat sections was performed as described elsewhere (Zikiryakhodzhaev et al., 1987) . The results were evaluated using a Leitz microscope (FRG) . The immunoenzyme staining of tumour sections was by the standard procedure reported elsewhere (Bourne, 1983) . Tumour sections were fixed in acetone at 4'C for 10 min, with subsequent stages at room temperature. The sections were incubated in medium 199, pH 7.2-7.4 for 10 min, and thereafter the endogenous peroxidase of cells was inhibited using 3% solution of hydrogen peroxide. Mabs were incubated for 30min and washed in medium 199 for 10min. Peroxidaselabelled antisera against mouse globulins was added for 30min and washed in medium 199 for 10min. The reaction was visualised using diaminobenzidine. Its solution was prepared and filtered ex tempora (1 mg in 2 ml of Tris-buffer Table I ). In the case of K20-tumour cells antigen-positive endothelial cells and lymphoid elements were noted in tumour sections.
According to the reaction pattern of ICO-10 and K20 Mabs, four groups of tumours can be distinguished. Table I summarises tumour immunophenotypes identified with the use of ICO-10 and K20 Mabs in combination. The following groups of solid tumours were identified: 1. this group includes neuroblastomas, malignant neurolemmomas, neurosarcomas and soft tissue sarcomas.
2. K20+ and ICO-10-: this group includes squamous cell cancer of the tongue and oesophagus, adrenal cortex adenoma, colon adenocarcinoma, hepatoblastoma and nephroblastoma.
3. this group includes immature teratoma, cervical and oesophageal leiomyoma.
4. ICO-10-and K20-: this group includes only two cases of malignant fibrous histiocytoma.
Discussion
The VLA family includes at least five distinct heterodimers, each composed of a unique a-subunit noncovalently associated with a common P-subunit. In our research we used K20, the best known antibodies recognising the common P-subunit. One of the functions of related molecules comprising the integrins superfamily is to mediate adhesion. Several members of VLA family have been shown to bind extracellular matrix proteins but the function of VLA-4 has been obscure as yet. VLA-4 is the only VLA molecule detected on resting T-cells. Recently (Groux et al., 1989) it has been shown that an antibody which recognises the P-subunit of VLA-4 (CD 29) on T-cells can inhibit CD4+ cell proliferation triggered via CD2 or CD3. VLA-4 functions in cell-to-cell interactions and serves the target for the suppressive effects exerted by CD8 on CD4 cells. Thus, the two types of antibodies used in our experiments, K20 (VLA-4) and ICO-10 (Thy-1) seem to be helpful for immunophenotyping of solid tumours when used in combination. These antibodies may be used as additional tools in the studies of human solid tumours alongside specific markers for malignant tumours, and the combination of the two antibodies seems helpful. The functional role of the antigens identified by these antibodies in tumour sections requires further studies.
